DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

7993 '03 NOV -5 A9:11

Re: Strattera
Docket No.: 03E-0261

The Honorable James E. Rogan
Under Secretary of Commerce for Intellectual Property and
Director of the United States Patent and Trademark Office
Box Pat. Ext.
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Director Rogan:

This is in regard to the application for patent term extension for U.S. Patent No. 5,658,590, filed by Eli Lilly & Company, under 35 U.S.C. section 156 et seq. We have reviewed the dates contained in the application and have determined the regulatory review period for Strattera, the human drug product claimed by the patent.

The total length of the regulatory review period for Strattera is 7,718 days. Of this time, 7,307 days occurred during the testing phase and 411 days occurred during the approval phase. These periods of time were derived from the following dates:

1. The date an exemption under subsection 505(i) of the Federal Food, Drug, and Cosmetic Act involving this drug product became effective: October 11, 1981.

   FDA has verified the applicant's claim that the date the investigational new drug application became effective was on October 11, 1981.

2. The date the application was initially submitted with respect to the human drug product under section 505(b) of the Federal Food, Drug, and Cosmetic Act: October 12, 2001.

   FDA has verified the applicant's claim that the new drug application (NDA) for Strattera (NDA 21-411) was initially submitted on October 12, 2001.

3. The date the application was approved: November 26, 2002.

   FDA has verified the applicant's claim that NDA 21-411 was approved on November 26, 2002.

03E-0261

LET 4

This determination of the regulatory review period by FDA does not take into account the effective date of the patent, nor does it exclude one-half of the testing phase as required by 35 U.S.C. section 156(c)(2).

Please let me know if we can be of further assistance.

Sincerely yours,

Jane A. Axelrad

Jane A. Axelrad
Associate Director for Policy
Center for Drug Evaluation and Research

cc: Charles E. Cohen
Eli Lilly & Company
Patent Division/CEC
Lilly Corporate Center
Indianapolis, IN 46285